Pacific Biosciences of California, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $335.5M | $81.6M |
| FY2021 | $896.1M | $791.0M | $460.7M |
| FY2022 | $896.7M | $562.9M | $325.1M |
| FY2023 | — | $701.3M | $179.9M |
| FY2024 | — | $506.6M | $55.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $335.5M | $81.6M |
| FY2021 | $896.1M | $791.0M | $460.7M |
| FY2022 | $896.7M | $562.9M | $325.1M |
| FY2023 | — | $701.3M | $179.9M |
| FY2024 | — | $506.6M | $55.4M |